Journal Article

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

Naseem Amin

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue 2, pages 340-345
Published in print February 2002 | ISSN: 0931-0509
Published online February 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.2.340
The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

Show Summary Details

Preview

Phosphorus control is a primary goal in the care of patients with end‐stage renal disease (ESRD). Sevelamer hydrochloride, a novel calcium‐free, aluminum‐free phosphate binder, allows physicians to control serum phosphorus in patients with ESRD without increasing serum calcium levels or contributing an excess calcium load. Clinical studies have shown that sevelamer provides sustained reduction in markers of soft‐tissue and cardiac calcification, specifically serum phosphorus, calcium×phosphorus product, parathyroid hormone and also improves blood lipid profiles. Thus, sevelamer hydrochloride offers the promise of impacting cardiac calcification and thereby reducing patient morbidity and mortality. Long‐term studies are underway to evaluate these potential benefits. This paper reviews sevelamer studies to date and addresses ongoing strategies for improving clinical management of phosphorus in ESRD.

Keywords: calcium; chronic renal failure; hyperphosphataemia; phosphate binder; phosphorus; sevelamer hydrochloride

Journal Article.  2772 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.